nChroma Stops First HBV Epigenetic Editing Study

nChroma disclosed November 18 that it stopped enrollment and dosing in its first CRMA-1001 hepatitis B study and is evaluating strategic alternatives. No efficacy, safety or CMC cause was disclosed, so the setback cannot…





